On the same day that health and wellness supplement provider Hims & Hers Health, Inc. announced it would begin selling a compounded semaglutide pill for weight loss at $49 for the first month, Novo Nordisk on Feb. 5 said it would take legal and regulatory action against the company for infringement of its intellectual property.
Novo Nordisk has manufactured its injectable drug Wegovy for weight loss since 2021 and announced on Jan. 5 that it would distribute the popular GLP-1 weight-loss drug as a daily oral pill.
